Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia

NCT01163916 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT01163916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01163916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia
Lead sponsor
Abbott
Phase
Observational
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2011
Enrollment
252 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis